| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H9FN2 |
| Molecular Weight | 236.2438 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NC(=CC=C1)C#CC2=CC(F)=CC(=C2)C#N
InChI
InChIKey=ZGEXQIMQZVRTDZ-UHFFFAOYSA-N
InChI=1S/C15H9FN2/c1-11-3-2-4-15(18-11)6-5-12-7-13(10-17)9-14(16)8-12/h2-4,7-9H,1H3
| Molecular Formula | C15H9FN2 |
| Molecular Weight | 236.2438 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
MFZ 10-7 is a high affinity negative allosteric modulator at the mGlu5 receptor (Ki = 0.67 nM). MFZ 10-7 demonstrates anxyolitic properties in mouse models. Intraperitoneal administration of MFZ 10-7 inhibited intravenous cocaine self-administration, cocaine-induced reinstatement of drug-seeking behavior and cocaine-associated cue-induced cocaine-seeking behavior in rats.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
For anxyolitic tests MFZ 10-7 was delivered via ip injection 15 min prior to testing. Anxyolitic effects were observed at dose 0.3 mg/kg.
Route of Administration:
Intraperitoneal
